CSL Shares Drop 18% After $5bn Impairment

CSL (ASX:CSL) shares fell 17.7% to A$98.59, hitting a 9.5‑year low and dragging the ASX 200 down 1%.
The company cut its FY2026 profit outlook to $3.1 bn (down from $3.3 bn) and revenue to $15.2 bn, revising prior 4‑7% profit and 2‑3% revenue growth forecasts.
CSL will record roughly $5 bn non‑cash impairments in FY2026‑27, featuring a major write‑down of its Vifor kidney unit.
CEO Gordon Naylor cited conditions and Middle East conflict; shares are down ~50% YTD amid US flu vaccine slump and generic competition.